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Abstract
Introduction: The aim of the study was to examine the frequency of methylation
status in promoter regions of p16 and DAPK genes in patients with non-invasive
bladder cancer. 
Material and methods: Forty-two patients (92.9% men, 73.8% smokers, 71.4%
T1G1, 19.1% T1G2, 9.5% T1G3) and 36 healthy controls were studied. Isolation of
genomic DNA from blood serum and methylation-specific PCR (MSP) were
applied. Methylation status – methylated and unmethylated promoter regions
of p16 and DAPK genes were analysed.
Results: Seventeen out of 42 patients (40.5%) had the methylated p16 gene,
while methylation of the DAPK gene was seen in 27 of 42 cases (64.3%). 
In 12 patients (28.6%) both analysed genes were methylated. A statistically
significant (p = 0.046) higher frequency of DAPK gene methylation (71.4%) was
observed in patients with lower grade (G1) bladder cancer. 
Conclusions: Detection of the aberrant hypermethylation of DAPK and p16 genes
in blood DNA from non-invasive bladder cancer patients might offer an effective
means for earlier auxiliary diagnosis of the malignancy. 
Key words: non-invasive bladder cancer, DAPK, p16, hypermethylation, methylation-
specific PCR.
Introduction
During the last two decades, research concerning the aetiology of cancer
disease has been considering not only causes such as carcinogen or
mutagen damage of DNA, but also the processes of non-genotoxic cancer
aetiology. It is suggested that epigenetic changes which concern inherited
changes of gene expression are not connected with changes in the genome
sequence.
Epigenetic control of gene transcription includes methylation of the DNA
and covalent modifications, such as acetylation and methylation, of
chromatin’s histone proteins [1, 2]. Both mechanisms are closely linked to
each other. Hypomethylation of the genomic DNA, which is connected to the
activation of the oncogene, as well as hypermethylation of the promoter
regions or exons of tumour suppressor genes, are observed in neoplastic cells. 
Excessive methylation of CpG islands was found in anti-oncogene
promoter regions, which were associated with the repair of damaged DNA
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DAPK and p16 hypermethylation in bladder cancer patients
(MLH1, 06-MGMT, BRCA1), metastases and inva  -
siveness of the cancer genesis process (E-cad herin,
VHL, APC) metabolism of xenobiotics (GSTP1),
apoptosis (DAPK), cell cycle (Rb, p16, p15, p14, p73)
and other cell processes (ER, RAR-β) of patients
with varied tumour locations [3].
It is suggested that changes in the degree of
methylation of DNA in cancer disease may
determine the process of cancer genesis, mainly
due to ‘silencing’ of the transcription process.
The product of the DAPK gene is considered to
be a positive mediator of apoptosis, and moreover
it is connected with the suppression of neoplastic
processes [4, 5]. The p16INK4a protein belongs to
a family of regulators of the cell cycle, called cyclin-
dependent kinase inhibitors (CDKI), which bind
themselves to cyclin-CDK complexes. The formation
of such complexes causes, as a result, the arrest of
the cell cycle in the G1 phase. This is also the way
through which the p16INK4a protein can stop the
proliferation of neoplastic cells [6].
The aim was to examine the frequency of
hypermethylation in promoter regions of p16 and
DAPK genes in patients with non-invasive bladder
cancer. 
Material and methods
Forty-two patients, citizens of central Poland,
with non-invasive urinary bladder cancer, of
different grading (G) were examined. Methylation
of promoter regions of the p16 anti-oncogene,
a gene involved in the regulation of the cell cycle,
and the DAPK gene (death-associated protein
kinase), which is involved in processes of
programmed cell death, was analysed. The
histopathological classification of urinary bladder
cancer was confirmed by two independent
histopathologists. 
The reference group, chosen on the basis of age
and gender, consisted of 36 healthy control
volunteers. Before blood samples were taken,
participants of the study were interviewed with
a questionnaire. The questionnaire included
questions concerning demographic data, place of
residence, history of cigarette addiction and of
employment.
The majority of patients in the control group
(91.7%) and the study group (92.9%) were men. In
the group with urinary bladder cancer 73.8% people
smoked cigarettes and in the reference group the
smokers constituted 69.4% of the group. In the
group of patients with non-invasive urinary bladder
cancer, most cases (71.4%) were characterized by
a low degree of neoplasm and clinical progression
(T1G1). The characteristics of both groups as well
as data concerning the clinical progression and the
degree of neoplasm in patients with urinary bladder
cancer are presented in Table I.
Permission to conduct the research was granted
by the Local Ethics Commission of Scientific
Research (Resolution no. 25/2003 dated 2.06.2003).
After being acquainted with the aim and the
methods used in the study, as well as the possibility
to quit the study at any desired moment, each of
the patients included in the study or reference
group signed a written informed consent form. 
Before any treatment, peripheral blood samples
were taken from both groups of patients. 
In order to detect the methylation status of the
two chosen genes, specifically the p16 and the
DAPK gene, in peripheral blood, the MSP method
(methylation-specific PCR) was used.
Blood samples collected from each participant
were stored at –70°C before DNA isolation. DNA
samples were extracted from 200 μl of blood serum
using the procedures of QIAamp DNA Blood Mini
Kit (Syngen Biotech, Poland). Sodium bisulfite
conversion of 1 μg of genomic DNA was performed
with CpGenome Modification Kit (Millipore, Biokom,
Poland). After bisulfite conversion, the methylation
analysis was conducted by the MSP assay. Primers
for determination of methylated or unmethylated
p16 and  DAPK  alleles have been described
elsewhere [7-9]. A nested, two-stage PCR approach
was used for p16 methylation status analysis
described by Palmisano et al. After 1st stage PCR
with primers specific to methylated or
unmethylated template, 280-bp products were 50-
fold diluted and 2 μl of diluted amplicons were used
in the 2nd stage PCR. Primer sequences, product
sizes and annealing temperatures used for MSP
analysis are presented in Table II. The methylation
status of the p16 was determined with Ampli  -
TaqGold polymerase (Applied Biosystems, Poland)
Table I. Characteristics of studied groups
1Student’s t-test and Mann-Whitney U test, NS – not significant, 
2χ2 test, NS – not significant
Bladder cancer  Control group
[pts]
N 42 36
Sex2: Males 39 (92.9%) 33 (91.7%)
Females 3 (7.1%) 3 (8.3%)
Age1 66.5 ±10.4  57.0 ±17.2 
(51-92) (37-83)
BMI1 26.1 ±3.9  25.7 ±4.0 
(17.7-36.3) (20.8-34.0)
SmokingY es 31 (73.8%) 25 (69.4%)
habit2:
No 11 (26.2%) 11 (30.6%)
Histopathology T1 42 (100%) –
G1 30 (71.4%) –
G2 8 (19.1%) –
G3 4 (9.5%) –514 Arch Med Sci 3, June / 2011
and of the DAPK gene with HotStarTaq polymerase
(Qiagen, Syngen Biotech, Poland) in a 20 μl volume.
CpGenome universal methylated DNA (Millipore,
Biokom, Poland) served as a positive control of
methylated alleles.
After amplification, PCR products were electro  -
phoresed on 1% agarose with ethidium bromide
along with DNA ladder and then visualized and
analysed. Samples with ambiguous results were re-
tested and 10% of all samples were repeated. 
To analyse the material, the χ2 test, Student’s 
t-test and non-parametric Mann-Whitney-U test
were used. Statistical significance was defined as
a value p < 0.05.
Results
Analysis of the profile of methylation in patients
with urinary bladder cancer shows that 17 out of 42
patients (40.5%) presented hypermethylation of the
p16 gene, while methylation of the DAPK gene was
seen in 27 of 42 cases (64.3%). In the case of 12
patients (28.6%) both analysed genes were
methylated, and in the case of 10 patients (23.8%),
promoter regions of p16 and DAPK genes were
unmethylated. A statistically significant (p = 0.046)
higher frequency of hypermethylation of the DAPK
gene (71.4%) was observed in patients with low
grade (G1) urinary bladder cancer in comparison to
patients with the G2 and G3 form (55%). Such
a dependency was not observed in the case of p16
gene methylation. A statistically significant
difference in the frequency of hypermethylation of
the p16 and DAPK genes was not seen in asso  -
ciation with age and cigarette smoking. 
Methylation of the p16 and DAPK genes was not
observed in blood serum of patients from the
control group. Table III presents the results of
hypermethylation of promoter regions in the p16
and DAPK genes. 
Discussion
It has been suggested that changes in the
degree of methylation in DNA regulatory regions,
observed during the course of neoplastic disease,
can influence the process of cancer genesis through
‘silencing’ of the process of transcription. Some
studies have found that the hypermethylation of
promoter regions mainly involves genes responsible
for control of the cell cycle and apoptosis, DNA
damage repairing genes, and genes connected with
the metabolism of xenobiotics [7].
In the presented project, the anti-oncogene p16
and DAPK were chosen to analyse the hyper  -
methylation of promoter regions in genomic DNA
isolated from blood serum of bladder cancer
patients. The p16 gene is involved in the regulation
of the cell cycle while the DAPK gene is committed
Zbigniew Jabłonowski, Edyta Reszka, Jolanta Gromadzińska, Wojciech Wąsowicz, Marek Sosnowski
T
a
b
l
e
 
I
I
.
P
r
i
m
e
r
 
s
e
q
u
e
n
c
e
,
 
p
r
o
d
u
c
t
 
s
i
z
e
 
a
n
d
 
a
n
n
e
a
l
i
n
g
 
t
e
m
p
e
r
a
t
u
r
e
 
u
s
e
d
 
f
o
r
 
M
S
P
N
 
–
 
n
e
s
t
e
d
 
P
C
R
 
p
r
i
m
e
r
,
 
M
 
–
 
m
e
t
h
y
l
a
t
e
d
-
s
p
e
c
i
f
i
c
 
p
r
i
m
e
r
,
 
U
 
–
 
u
n
m
e
t
h
y
l
a
t
e
d
-
s
p
e
c
i
f
i
c
 
p
r
i
m
e
r
G
e
n
e
F
o
r
w
a
r
d
 
p
r
i
m
e
r
 
(
F
)
 
(
5
’
 
→
3
’
)
R
e
v
e
r
s
e
 
p
r
i
m
e
r
 
(
R
)
 
(
5
’
 
→
3
’
)
A
n
n
e
a
l
i
n
g
 
t
e
m
p
e
r
a
t
u
r
e
 
[
°
C
]
P
r
o
d
u
c
t
 
s
i
z
e
 
[
b
p
]
R
e
f
.
p
1
6
N
1
F
 
G
A
A
G
A
A
A
G
A
G
G
A
G
G
G
G
T
T
G
G
N
R
 
C
T
A
C
A
A
A
C
C
C
T
C
T
A
C
6
0
2
8
0
P
a
l
m
i
s
a
n
o
 
e
t
 
a
l
.
,
 
2
0
0
0
M
2
F
 
T
T
A
T
T
A
G
A
G
G
G
T
G
G
G
G
C
G
G
A
T
C
G
C
M
R
 
G
A
C
C
C
C
G
A
A
C
C
G
C
G
A
C
C
G
T
A
A
6
5
1
5
0
H
e
r
m
a
n
 
e
t
 
a
l
.
,
 
1
9
9
6
U
3
F
 
T
T
A
T
T
A
G
A
G
G
G
T
G
G
G
G
T
G
G
A
T
T
G
T
U
R
 
C
A
A
C
C
C
C
A
A
A
C
C
A
C
A
A
C
C
A
T
A
A
6
0
1
5
1
D
A
P
K
M
F
 
G
G
A
T
A
G
T
C
G
G
A
T
C
G
A
G
T
T
A
A
C
G
T
C
M
R
 
C
C
C
T
C
C
C
A
A
A
C
G
C
C
G
A
5
6
9
8
E
s
t
e
l
l
e
r
 
e
t
 
a
l
.
,
 
1
9
9
9
U
F
 
G
G
A
G
G
A
T
A
G
T
T
G
G
A
T
T
G
A
G
T
T
A
A
T
G
T
T
U
R
 
C
A
A
A
T
C
C
C
T
C
C
C
A
A
A
C
A
C
C
A
A
6
1
1
0
6Arch Med Sci 3, June / 2011 515
DAPK and p16 hypermethylation in bladder cancer patients
to a process of programmed cell death. p16 and
DAPK genes are closely connected with the process
of cancer genesis, by inducing the suppression of
cell proliferation. So far, in Poland, research
concerning the promoter hypermethylation of
genomic DNA from blood has not been conducted.
At the same time, in world literature, the role of
epigenetic regulation of the p16 and DAPK genes
in urinary bladder cancer has not been completely
explained. 
Past researchers have used neoplastic tissues to
estimate the degree of DNA hypermethylation.
Many authors claim that peripheral blood, serum
and plasma can be good diagnostic material for the
detection of changes, such as DNA hyper  -
methylation, in nucleic acids [8-10]. Valenzuela et
al. observed a statistically significant dependence
between the methylation of p16 in the promoter
region in tissue and plasma, while examining 
86 people with urinary bladder cancer. Dominguez
et al. achieved similar results, assessing, among
other things, the hypermethylation of promoter p14
and  p16 regions in 27 urinary bladder cancer
patients [11]. 
Excessive methylation of CpG islands (cytosine,
phosphorylated guanine), which occurs in the
promoter regions, is observed in various types of
tumours. As a consequence, hypermethylation can
lead to the decrease of transcription activity of
specific genes and can play an important role in the
induction of the cancer genesis process. Some
authors claim that even up to 65% of cases of
neoplastic disease may be linked to these epige  -
netic changes [9].
Hypermethylation of promoter regions in the p16
and DAPK genes does not occur in healthy people.
This confirms our observations. 
Many authors have observed hypermethylation,
in 7% to 60% of cases, of the p16 gene, in patients
with urinary bladder cancer [12-16]. In our study,
patients with urinary bladder cancer, in whom
hypermethylation of the p16 gene was seen, made
up 40.5%. 
In the case of DAPK, hypermethylation was found
in 4% to 45.5% of patients with urinary bladder cancer
[14-16], but when counting all of the patients
examined in our centre, this proportion was 64.3%.
The observed variation could be the result of
differences in the sensitivity of our method of
detection of DNA methylation as well as of the
heterogeneity of the sample taken [17]. Some of the
authors also paid attention to the correlation between
DNA methylation and the time of progression of the
neoplastic disease. Higher frequency of hyper  -
methylation in the DAPK gene was observed in the
beginning stages of neoplastic disease [18-21]. 
Tada et al. claimed that the assessment of the
changes in DAPK methylation can be a prognostic
factor of non-invasive urinary bladder cancer
recurrences [22]. They proved that the percentage
of recurrences of the disease was 88% among
those patients in whom DAPK hypermethylation
was found, while it was only 28% among those
patients in whom gene methylation was not seen.
We observed a higher frequency in DAPK gene
hypermethylation (71.4%) among patients with
urinary bladder cancer of lower malignancy (grade
G1) in comparison to patients with grades G2 and
G3 (55%). A longer follow-up of these patients could
help us explain the above observations.
In conclusion, detection of the aberrant
methylation of DAPK and p16 genes in blood DNA
from non-invasive bladder cancer patients might
offer an effective means for the earlier auxiliary
diagnosis of the malignancy. The usefulness of the
above-mentioned research, in clinical practice, still
has to be evaluated. 
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